Typhoid Clinical Trial
Official title:
A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children
This is a Phase I, Randomized, observer-blinded, age de-escalating study.
The study objectives are:
1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and
4 weeks.
2. To assess the immunogenicity of 25 μg of Vi-DT typhoid conjugate vaccine administered at
0 and 4 weeks.
3. To compare the safety and immunogenicity of Vi-DT and Vi-Polysaccharide typhoid
vaccines.
This study will be carried out in healthy adults and children at a single site. Subjects will
be stratified according to age.
The study procedure is as follows:
Visit 1 (day-1 to -7): Screen participants by medical history, physical examination and lab
investigations. Collect blood for safety and immunogenicity assessments.
Visit 2 (day 0): Enroll, randomize and administer first dose of vaccine to eligible
participants
Visit 3 (day 3): Assess participant safety by medical history and physical examination
Visit 4 (day 7): Record solicited adverse reaction 7 days post vaccination, and collect blood
for safety lab assessments.
Visit 5 (day 28): Assess participant safety, collect blood for immunogenicity assessments,
and administer second vaccine dose
Visit 6 (day 31): Participants safety will be assessed by medical history and physical
examination
Visit 7 (day 35): Record solicited adverse reaction 7 days post second vaccination.
Visit 8 (day 56): Collect blood for immunogenicity assessments, assess participant safety,
and fill in study completion form in the absence of any safety concern.
This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two
distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine
administrator.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03312699 -
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
|
Phase 1 | |
| Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
| Completed |
NCT00131833 -
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
|
Phase 4 | |
| Completed |
NCT00125047 -
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
|
Phase 4 | |
| Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Active, not recruiting |
NCT03933098 -
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
|
Phase 3 | |
| Completed |
NCT00679172 -
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
|
Phase 2 | |
| Completed |
NCT00125008 -
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
|
Phase 4 | |
| Recruiting |
NCT04878549 -
Transcriptomic Responses for the Identification of Pathogens
|
||
| Recruiting |
NCT05475379 -
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
|
Phase 1/Phase 2 | |
| Completed |
NCT04204096 -
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
|
Phase 3 | |
| Active, not recruiting |
NCT03299426 -
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
|
Phase 3 | |
| Completed |
NCT01019083 -
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
|
Phase 1/Phase 2 | |
| Completed |
NCT03614533 -
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
|
Phase 2 | |
| Completed |
NCT00131820 -
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
|
Phase 4 | |
| Completed |
NCT03527355 -
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
|
Phase 2 |